Andreas Gollner

Boehringer Ingelheim (Austria) — Austria

Medicine · Health Sciences

17h-index1.4kcitations65works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(29), Protein Degradation and Inhibitors(8), Synthetic Organic Chemistry Methods(6), Cancer Research and Treatments(6), Click Chemistry and Applications(5)

Publications65 total

Table S12 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Data from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S10 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Figure S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Figure S2 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Figure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S4 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S8 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S13 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Figure S4 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S2 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S3 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Figure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Table S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024Open Access
Supplementary Methods from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
2024· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Darryl B. McConnell(25), Dorothea Rudolph(22), Harald Weinstabl(21), Ulrike Weyer-Czernilofsky(19), Jens Quant(17), Jürgen Ramharter(17), Norbert Kraut(16), Guido Boehmelt(13), Daniel Gerlach(13), Rolf Grempler(13), Alejandro Pérez Pitarch(13), Bojana Golubović(13), Gerd Bader(13), Patrizia Sini(13), Joerg Rinnenthal(12), Rosa Baumgartinger(12), Peter Jung(12), Kristiane Wetzel(12), S. R. Otto(12), Christian Mandl(12)